We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current 0ILL market cap is 847.96M. The company's latest EPS is EUR 2.6716 and P/E is 24.65.
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 419.96M | 648.68M | 817.7M | 829.51M | 763.75M |
| Operating Income | 73.49M | 181.57M | 256.05M | 220.13M | 179.4M |
| Net Income | 61.06M | 153.08M | 199.67M | 170.34M | 136.88M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 574.44M | 732.68M | 878.7M | 799.88M | 832.02M |
| Total Liabilities | 200.74M | 261.7M | 357.32M | 256.39M | 250.48M |
| Total Equity | 373.7M | 470.98M | 521.38M | 543.49M | 581.54M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 48.88M | 149.44M | 237.6M | 113.25M | 138.28M |
| Investing | -39.63M | -40.84M | -57.15M | -52.03M | -81.06M |
| Financing | -21.52M | -62.73M | -154.54M | -160.84M | -55.36M |
| Market Cap | 847.96M |
| Price to Earnings Ratio | 24.65 |
| Price to Sales Ratio | 4.42 |
| Price to Cash Ratio | 124.12 |
| Price to Book Ratio | 5.8 |
| Dividend Yield | - |
| Shares Outstanding | 51.24M |
| Average Volume (1 week) | 1.65k |
| Average Volume (1 Month) | 5.94k |
| 52 Week Change | 0.00% |
| 52 Week High | 16.55 |
| 52 Week Low | 16.55 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Laboratorios Farmaceuticos Rovi Sa |
| Address |
calle julian camarillo, 35 madrid, community of madrid 28223 |
| Website | https://www.rovi.es |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
